ArticleLeukemia2024

Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms.

Tracy Murphy et al.PubMed ↗Publisher ↗

No numbers read from the abstract.